Emerging Role of Circulating Tumour DNA in Treatment Response Prognosis in Colon Cancer
- 11 June 2021
- book chapter
- Published by Springer Nature
- p. 257-270
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- Establishment of tumor‐specific copy number alterations from plasma DNA of patients with cancerInternational Journal of Cancer, 2013
- Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkersCancer Medicine, 2012
- Biomarkers for Colorectal CancerInternational Journal of Molecular Sciences, 2010
- Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal CancerClinical Chemistry, 2009
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysisNature Biotechnology, 2008
- Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative DisordersThe Journal of Molecular Diagnostics, 2007
- Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cellsNature Genetics, 2005
- Methylation of Mouse Liver DNA Studied by Means of the Restriction Enzymes Msp I and Hpa IIScience, 1979